Chloroquine diphosphate: a risk factor for herpes zoster in patients with dermatomyositis/polymyositis

Imagem de Miniatura
Arquivos
art_SOUZA_Chloroquine_diphosphate_a_risk_factor_for_herpes_zoster_2013.PDF (297.16 KB)
Citações na Scopus
7
Tipo de produção
article
Data de publicação
2013
DOI
SciELO
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
HOSPITAL CLINICAS, UNIV SAO PAULO
Autores
CUNHA, Gilmara Franco da
Citação
CLINICS, v.68, n.5, p.621-627, 2013
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
OBJECTIVES: Herpes zoster has been widely described in the context of different systemic autoimmune diseases but not dermatomyositis/polymyositis. Therefore, we analyzed the prevalence, risk factors and herpes zoster outcomes in this population. METHOD: A retrospective cohort study of herpes zoster infections in dermatomyositis/polymyositis patients was performed. The patients were followed at a tertiary center from 1991 to 2012. For the control group, each patient with herpes zoster was paired with two patients without herpes zoster. Patients were matched by gender and the type of myositis, age at myositis onset and disease duration. RESULTS: Of 230 patients, 24 (10.4%) had a histories of herpes zoster (19 with dermatomyositis and five with polymyositis, two-thirds female). The mean age of the patients with herpes zoster was 44.6 +/- 16.8 years. No difference between the groups was found regarding cumulative clinical manifestations. Disease activity, autoantibody, muscle and leukogram parameters were also comparable between the groups. No differences in immunosuppressive (alone or in association with other immunosuppressive therapies) or glucocorticoid (current use, medium dose and cumulative dose in the last two months) therapies were found between patients with and without herpes zoster. However, a higher proportion of patients in the herpes zoster group received chloroquine diphosphate compared to the control group. All of the patients received acyclovir; 58.3% of patients had postherpetic neuralgia and no cases of recurrence were reported. Furthermore, individuals who were taking high prednisone doses at the time of the herpes zoster diagnosis had reduced levels of postherpetic neuralgia. CONCLUSIONS: These data suggest that chloroquine diphosphate could predispose patients with dermatomyositis/polymyositis to developing herpes zoster, particularly women and dermatomyositis patients.
Palavras-chave
Antimalarial, Chloroquine Diphosphate, Dermatomyositis, Herpes Zoster, Risk Factors
URI
https://observatorio.fm.usp.br/handle/OPI/2296
Referências
  1. Ang GC, 2005, ARCH DERMATOL, V141, P855, DOI 10.1001/archderm.141.7.855
  2. Arvin A, 2005, NEW ENGL J MED, V352, P2266, DOI 10.1056/NEJMp058091
  3. Boelaert JR, 2001, J CLIN VIROL, V20, P137, DOI 10.1016/S1386-6532(00)00140-2
  4. BOHAN A, 1975, NEW ENGL J MED, V292, P344, DOI 10.1056/NEJM197502132920706
  5. Borba EF, 2010, JCR-J CLIN RHEUMATOL, V16, P119, DOI 10.1097/RHU.0b013e3181d52ed7
  6. BOTET JCP, 1988, VIRCHOWS ARCH A, V412, P371
  7. Callen JP, 1995, DERMATOLOGICAL SIGNS, P13
  8. Dworkin RH, 2001, HERPES ZOSTER POSTHE, P39
  9. EMSLIESMITH AM, 1990, ANN NEUROL, V27, P343, DOI 10.1002/ana.410270402
  10. ENGEL AG, 1986, HUM PATHOL, V17, P704, DOI 10.1016/S0046-8177(86)80180-0
  11. Ernst ME, 1998, ANN PHARMACOTHER, V32, P1099, DOI 10.1345/aph.18041
  12. Fardet L, 2009, ARCH DERMATOL, V145, P889, DOI 10.1001/archdermatol.2009.152
  13. Fox RI, 1996, LUPUS, V5, pS31
  14. KAHL LE, 1994, J RHEUMATOL, V21, P84
  15. Kang TY, 2005, RHEUMATOL INT, V25, P97, DOI 10.1007/s00296-003-0403-3
  16. Keyaerts E, 2004, BIOCHEM BIOPH RES CO, V323, P264, DOI 10.1016/j.bbrc.2004.08.085
  17. Koetz K, 2000, P NATL ACAD SCI USA, V97, P9203, DOI 10.1073/pnas.97.16.9203
  18. Kost RG, 1996, NEW ENGL J MED, V335, P32
  19. Lee PPW, 2006, PEDIATR INFECT DIS J, V25, P728, DOI 10.1097/01.inf.0000226841.03751.1f
  20. MANZI S, 1995, J RHEUMATOL, V22, P1254
  21. Marie I, 2011, SEMIN ARTHRITIS RHEU, V41, P48, DOI 10.1016/j.semarthrit.2010.08.003
  22. McCrary ML, 1999, J AM ACAD DERMATOL, V41, P1, DOI 10.1016/S0190-9622(99)70398-1
  23. McDonald JR, 2009, CLIN INFECT DIS, V48, P1164
  24. Meinao IM, 1996, LUPUS, V5, P237, DOI 10.1177/096120339600500313
  25. MOGA I, 1995, REV CLIN ESP, V195, P530
  26. Nagaoka S, 1990, Kansenshogaku Zasshi, V64, P1394
  27. Noss EH, 2006, J RHEUMATOL, V33, P1021
  28. OLSON NY, 1989, J RHEUMATOL, V16, P1545
  29. Opstelten W, 2007, PAIN, V132, pS52, DOI 10.1016/j.pain.2007.02.004
  30. Pelle MT, 2002, ARCH DERMATOL, V138, P1231, DOI 10.1001/archderm.138.9.1231
  31. Ryes RI., 1997, BR J RHEUMATOL, V36, P799
  32. Sato JO, 2009, CLIN EXP RHEUMATOL, V27, P1031
  33. Savirno A, 2003, LANCET INFECT DIS, V3, P772
  34. Seth P, 1999, AM J TROP MED HYG, V61, P180
  35. Smitten AL, 2007, ARTHRIT RHEUM-ARTHR, V57, P1431, DOI 10.1002/art.23112
  36. Strangfeld A, 2009, JAMA-J AM MED ASSOC, V301, P737, DOI 10.1001/jama.2009.146
  37. Thomas SL, 2004, LANCET INFECT DIS, V4, P26, DOI 10.1016/S1473-3099(03)00857-0
  38. Vincent MJ, 2005, VIROL J, V2, DOI 10.1186/1743-422X-2-69
  39. Wolfe F, 2006, RHEUMATOLOGY, V45, P1370, DOI 10.1093/rheumatology/ke1328
  40. WOO TY, 1984, J AM ACAD DERMATOL, V10, P592, DOI 10.1016/S0190-9622(84)80263-7
  41. Yu KH, 2011, CLIN RHEUMATOL, V30, P1595, DOI 10.1007/s10067-011-1840-0

Coleções
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/17
Artigos e Materiais de Revistas Científicas - ODS/03